Alexion Pharmaceuticals (ALXN) : Jennison Associates reduced its stake in Alexion Pharmaceuticals by 2.96% during the most recent quarter end. The investment management company now holds a total of 7,093,395 shares of Alexion Pharmaceuticals which is valued at $976,476,756 after selling 216,732 shares in Alexion Pharmaceuticals , the firm said in a disclosure report filed with the SEC on Aug 3, 2016.Alexion Pharmaceuticals makes up approximately 1.02% of Jennison Associates’s portfolio.
Other Hedge Funds, Including , Magee Thomson Investment Partners reduced its stake in ALXN by selling 4,540 shares or 10.04% in the most recent quarter. The Hedge Fund company now holds 40,670 shares of ALXN which is valued at $5,116,286. Alexion Pharmaceuticals makes up approx 1.70% of Magee Thomson Investment Partners’s portfolio.Nordea Investment Management Ab reduced its stake in ALXN by selling 87,579 shares or 90.72% in the most recent quarter. The Hedge Fund company now holds 8,958 shares of ALXN which is valued at $1,137,039.Mai Capital Management boosted its stake in ALXN in the latest quarter, The investment management firm added 1,358 additional shares and now holds a total of 4,281 shares of Alexion Pharmaceuticals which is valued at $537,094. Alexion Pharmaceuticals makes up approx 0.04% of Mai Capital Management’s portfolio.Nn Investment Partners Holdings N.v. reduced its stake in ALXN by selling 38,714 shares or 55.65% in the most recent quarter. The Hedge Fund company now holds 30,850 shares of ALXN which is valued at $3,809,050. Alexion Pharmaceuticals makes up approx 0.04% of Nn Investment Partners Holdings N.v.’s portfolio.
Alexion Pharmaceuticals closed down -1.03 points or -0.75% at $136.08 with 11,71,458 shares getting traded on Monday. Post opening the session at $137.14, the shares hit an intraday low of $135.69 and an intraday high of $138.05 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Alexion Pharmaceuticals reported $1.13 EPS for the quarter, missing the analyst consensus estimate by $ -0.04 based on the information available during the earnings call on Jul 28, 2016. Analyst had a consensus of $1.17. The company had revenue of $753.10 million for the quarter, compared to analysts expectations of $743.05 million. The company’s revenue was up 18.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.44 EPS.
Many Wall Street Analysts have commented on Alexion Pharmaceuticals. Shares were Reiterated by Stifel on Jul 29, 2016 to “Buy” and Lowered the Price Target to $ 182 from a previous price target of $195 .Shares were Reiterated by Barclays on Jul 29, 2016 to “Equal Weight” and Lowered the Price Target to $ 150 from a previous price target of $165 .RBC Capital Mkts Initiated Alexion Pharmaceuticals on Jul 13, 2016 to “Outperform”, Price Target of the shares are set at $188.
Alexion Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. As of June 23 2015 the Company had eight product candidates in clinical trials for 11 indications. The Company’s product pipeline includes complement inhibitor portfolio metabolic rare disease portfolio and preclinical candidates. Its complement inhibitor portfolio includes Soliris ALXN1007 ALXN1210 and ALXN5500. Its metabolic rare disease portfolio includes Strensiq Kanuma ALXN1101 and SBC-103. The Company’s preclinical candidates include mRNA Therapies SBC-105 and other complement inhibitors. Its Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) two life-threatening ultra-rare disorders.